1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Farmacologia, Toxicologia i Química Terapèutica
  4. Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/162264
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVázquez Carrera, Manuel-
dc.date.accessioned2020-05-25T11:07:48Z-
dc.date.available2020-05-25T11:07:48Z-
dc.date.issued2016-03-20-
dc.identifier.issn1043-2760-
dc.identifier.urihttp://hdl.handle.net/2445/162264-
dc.description.abstractInsulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) development. Preclinical evidence suggests that peroxisome proliferator-activated receptor (PPAR) β/δ activators may prevent and treat obesity-induced insulin resistance and T2DM, while clinical trials highlight their potential utility in dyslipidemia. This review summarizes recent mechanistic insights into the antidiabetic effects of PPARβ/δ activators, including their anti-inflammatory actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as their capacity to activate pathways that are also stimulated by exercise. Findings from clinical trials are also examined. Dissecting the effects of PPARβ/δ ligands on insulin sensitivity and atherogenesis may provide a basis for the development of therapies for the prevention and treatment of T2DM and cardiovascular disease (CVD).-
dc.format.extent16 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier Current Trends-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.tem.2016.02.008-
dc.relation.ispartofTrends in Endocrinology and Metabolism, 2016, vol. 27, num. 5, p. 319-334-
dc.relation.urihttps://doi.org/10.1016/j.tem.2016.02.008-
dc.rightscc-by-nc-nd (c) Elsevier Current Trends, 2016-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)-
dc.subject.classificationDiabetis-
dc.subject.classificationResistència a la insulina-
dc.subject.classificationInflamació-
dc.subject.otherDiabetes-
dc.subject.otherInsulin resistance-
dc.subject.otherInflammation-
dc.titleUnraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec659283-
dc.date.updated2020-05-25T11:07:49Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid27005447-
Appears in Collections:Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
659283.pdf10.07 MBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons